Yanan Zhu
Stock Analyst at Wells Fargo
(3.34)
# 970
Out of 5,122 analysts
89
Total ratings
43.06%
Success rate
6.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPT RAPT Therapeutics | Downgrades: Equal-Weight | $58 | $57.75 | +0.43% | 8 | Jan 20, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $4.72 | +133.05% | 4 | Jan 5, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $100 | $84.59 | +18.22% | 4 | Jan 5, 2026 | |
| QURE uniQure | Maintains: Overweight | $80 → $60 | $27.80 | +115.83% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $17 → $12 | $13.05 | -8.05% | 7 | Nov 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $50 → $45 | $20.28 | +121.89% | 7 | Nov 5, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $7.32 | +173.22% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.06 | +94.17% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $32.99 | +36.40% | 1 | Aug 25, 2025 | |
| MGX Metagenomi Therapeutics | Maintains: Overweight | $16 → $12 | $1.49 | +705.37% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.16 | +115.52% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.38 | +262.32% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $2.64 | +430.30% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $72.93 | +2.84% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $27.89 | +150.99% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.91 | +156.08% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $33.29 | +20.16% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $52.00 | +25.00% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $9.97 | +200.90% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.39 | +925.64% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.58 | +17,341.86% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $851.68 | -61.72% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.32 | +578.29% | 2 | Oct 29, 2020 |
RAPT Therapeutics
Jan 20, 2026
Downgrades: Equal-Weight
Price Target: $58
Current: $57.75
Upside: +0.43%
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $4.72
Upside: +133.05%
Ionis Pharmaceuticals
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $84.59
Upside: +18.22%
uniQure
Nov 12, 2025
Maintains: Overweight
Price Target: $80 → $60
Current: $27.80
Upside: +115.83%
Intellia Therapeutics
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $17 → $12
Current: $13.05
Upside: -8.05%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $20.28
Upside: +121.89%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $7.32
Upside: +173.22%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.06
Upside: +94.17%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $32.99
Upside: +36.40%
Metagenomi Therapeutics
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.49
Upside: +705.37%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.16
Upside: +115.52%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.38
Upside: +262.32%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.64
Upside: +430.30%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $72.93
Upside: +2.84%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $27.89
Upside: +150.99%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.91
Upside: +156.08%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $33.29
Upside: +20.16%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $52.00
Upside: +25.00%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $9.97
Upside: +200.90%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.39
Upside: +925.64%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.58
Upside: +17,341.86%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $851.68
Upside: -61.72%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.32
Upside: +578.29%